L.L.C

Syneos Health, Inc. and Star Parent, Inc. Announce Proposed $1.70 Billion Offering of Senior Secured Notes

Retrieved on: 
Wednesday, September 6, 2023

MORRISVILLE, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Star Parent, Inc. (the “Issuer” or the “Company”) and Syneos Health, Inc. (“Syneos Health”), announced today that, subject to market conditions and other factors, the Issuer intends to offer $1,700,000,000 aggregate principal amount of Senior Secured Notes due 2030 (the “Notes”).

Key Points: 
  • MORRISVILLE, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Star Parent, Inc. (the “Issuer” or the “Company”) and Syneos Health, Inc. (“Syneos Health”), announced today that, subject to market conditions and other factors, the Issuer intends to offer $1,700,000,000 aggregate principal amount of Senior Secured Notes due 2030 (the “Notes”).
  • This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy the Notes.
  • Any offers of the Notes will be made only by means of a private offering circular.
  • This announcement does not constitute an offer to purchase with respect to any of Syneos Health’s existing securities or a notice of redemption with respect to any of Syneos Health’s existing securities.

Tivoli Midstream acquires NTX Gathering System from Phillips 66

Retrieved on: 
Monday, August 28, 2023

Tivoli Midstream LLC, (“Tivoli”) today announced the closing of an acquisition of a crude oil pipeline system in Northern Texas (“NTX”) from affiliates of Phillips 66 Company (PSX).

Key Points: 
  • Tivoli Midstream LLC, (“Tivoli”) today announced the closing of an acquisition of a crude oil pipeline system in Northern Texas (“NTX”) from affiliates of Phillips 66 Company (PSX).
  • NTX consists of approximately 140 miles of crude oil gathering and transportation pipelines and storage capacity in the Barnett Shale area of Northern Texas.
  • The system, which extends through portions of Young, Archer, Clay, Jack, Palo Pinto, Wichita and Stephens Counties, will be underpinned by a long-term transportation services agreement with Phillips 66.
  • “We are excited by our most recent acquisition of NTX, which Tivoli is ideally suited to operate,” said Rance Fromme, President of Tivoli.

Turning Point Global Solutions, L.L.C. (TurningPoint) announces its continued support for CMS' Call Center: Connect (C3) help desk services contract

Retrieved on: 
Monday, August 28, 2023

ROCKVILLE, Md., Aug. 28, 2023 /PRNewswire/ -- Turning Point Global Solutions, L.L.C. (TurningPoint) announces its continued support for CMS' Call Center: Connect (C3) help desk services contract as a significant subcontractor to Illumen-FWG, JV, LLC (Illumen). TurningPoint will continue to provide vital networking and operational support to ensure the Medicare and Marketplace contact centers systems remain accessible and effective. The C3 Help Desk is responsible for overseeing and managing the resolution of contact center representative requests for both the Medicare and Marketplace contact centers. These requests include, but are not limited to, troubleshooting support, technical support, issue triage, and escalation of issues. The C3 Help Desk is the central, integrated, help desk supporting the suite of systems that support the call centers. The C3 Help Desk is also responsible for managing the entire lifecycle of help desk requests. David Hughes, TurningPoint's managing partner, says the C3 contract remains a core component of the company's portfolio of services "As an integrated member of the Illumen team, we are proud that TurningPoint brings highly skilled personnel who have been providing C3 services since 2007," he said. "We bring unparalleled understanding of the C3 Help Desk environment to the Illumen team, as well as the necessary telecommunications and project expertise we have developed over these many years." Illumen's C3 Help Desk contract is a 60-month task order under the GSA STARS III contract vehicle with a total value of $10.9M if all options are exercised.

Key Points: 
  • TurningPoint continues its successful track record of service providing support for the Centers For the Medicare & Medicaid Services (CMS) Call Center:Connect (C3) Help Desk.
  • (TurningPoint) announces its continued support for CMS' Call Center: Connect (C3) help desk services contract as a significant subcontractor to Illumen-FWG, JV, LLC (Illumen).
  • The C3 Help Desk is the central, integrated, help desk supporting the suite of systems that support the call centers.
  • The C3 Help Desk is also responsible for managing the entire lifecycle of help desk requests.

Eyenovia Announces $12 Million Registered Direct Offering

Retrieved on: 
Thursday, August 24, 2023

The combined offering price for each share of common stock and accompanying warrant is $1.86, and the offering price for each pre-funded warrant and accompanying warrant is $1.85.

Key Points: 
  • The combined offering price for each share of common stock and accompanying warrant is $1.86, and the offering price for each pre-funded warrant and accompanying warrant is $1.85.
  • The proceeds from the Offering, before deducting the placement agents’ fees and other offering expenses payable by Eyenovia, are expected to be $12 million (excluding any proceeds that may be received upon the exercise of the warrants or the pre-funded warrants).
  • The Offering is expected to close on or about August 29, 2023, subject to the satisfaction of customary closing conditions.
  • All of the securities in the Offering are being sold by Eyenovia.

Orbital Infrastructure Group Inc. Intends to Enter into Purchase Agreements for the Sale of Front Line Power Construction and Gibson Technical Services and Files for Chapter 11 Protection

Retrieved on: 
Thursday, August 24, 2023

HOUSTON, Aug. 23, 2023 /PRNewswire/ -- Orbital Infrastructure Group Inc. (NASDAQ: OIG) (the "Company"), announced today that it and certain of its subsidiaries (Orbital Solar Services, L.L.C., Orbital Power, Inc., Orbital Gas Systems, North America, and Eclipse Foundation Group, Inc.) have filed voluntary Chapter 11 petitions in the U.S. Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court"). The filing specifically excludes Front Line Power Construction ("FLP") and Gibson Technical Services ("GTS"), which are being sold separately as described below.

Key Points: 
  • The filing specifically excludes Front Line Power Construction ("FLP") and Gibson Technical Services ("GTS"), which are being sold separately as described below.
  • The Company is seeking Bankruptcy Court approval of bidding procedures allowing for the submission of highest and best purchase offers.
  • Under the purchase agreements, successful purchasers will not acquire the Company's other subsidiaries (Orbital Infrastructure Group, Inc., Orbital Solar Services, L.L.C., Orbital Power, Inc., Orbital Gas Systems, North America, Eclipse Foundation Group, Inc.).
  • To provide necessary funding during the Chapter 11 proceeding, the Company has received commitments for two debtor-in-possession ("DIP") financing credit agreements with the FLP Lenders and the GTS Lender.

Granite Creek Capital Partners Announces Investment in Salem One

Retrieved on: 
Monday, August 14, 2023

CHICAGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Granite Creek Capital Partners, L.L.C.

Key Points: 
  • CHICAGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Granite Creek Capital Partners, L.L.C.
  • , a private investment firm based in Chicago, today announced it has made a new platform investment in Salem One, a leading provider of corporate communication solutions, including direct marketing, packaging, and logistics services.
  • Granite Creek partnered with Phil Kelley, Jr., CEO and President of Salem One, and Scott Mahoney, a long-time shareholder and previous Chairman of the company.
  • In conjunction with Granite Creek’s investment in Salem One, Granite Creek Partner Brian Boorstein and Director Jordan Liss joined its Board of Directors.

Bruker Corporation and PhenomeX Inc. Announce Definitive Agreement for Bruker to Acquire PhenomeX in All-Cash Transaction

Retrieved on: 
Thursday, August 17, 2023

Bruker Corporation (Nasdaq: BRKR) and PhenomeX Inc. (Nasdaq: CELL) today announced that they have signed a definitive agreement for Bruker to acquire PhenomeX for $1.00 per share in an all-cash transaction.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR) and PhenomeX Inc. (Nasdaq: CELL) today announced that they have signed a definitive agreement for Bruker to acquire PhenomeX for $1.00 per share in an all-cash transaction.
  • The proposed acquisition values PhenomeX at a total equity value of approximately $108 million.
  • PhenomeX is a functional cell biology company that provides single-cell biology research tools to deliver deep insights into cellular function and new perspectives on phenomes and genotype-to-phenotype linkages.
  • The PhenomeX products include the key Beacon® Optofluidic platform, as well as the IsoLight® and IsoSpark® proteomics barcoding platform.

Flywire Announces Pricing of Follow-On Offering

Retrieved on: 
Thursday, August 10, 2023

BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Flywire Corporation (Nasdaq: FLYW) (“Flywire” or the “Company”), a global payments enablement and software company, today announced the pricing of its underwritten public offering of 8,000,000 shares of its voting common stock (the “Common Stock”) at a price to the public of $32.00 per share.

Key Points: 
  • BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Flywire Corporation (Nasdaq: FLYW) (“Flywire” or the “Company”), a global payments enablement and software company, today announced the pricing of its underwritten public offering of 8,000,000 shares of its voting common stock (the “Common Stock”) at a price to the public of $32.00 per share.
  • Closing of the offering is expected to occur on August 14, 2023, subject to customary closing conditions.
  • In addition, Flywire has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of Common Stock at the public offering price less the underwriting discounts and commissions.
  • J.P. Morgan, Citigroup, BofA Securities, Raymond James, RBC Capital Markets and William Blair are acting as book-running managers for the offering.

Merus Announces Pricing of Public Offering of Common Shares

Retrieved on: 
Thursday, August 10, 2023

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an underwritten public offering of 6,818,182 common shares, at a public offering price of $22.00 per share (the “Offer Shares”).

Key Points: 
  • UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an underwritten public offering of 6,818,182 common shares, at a public offering price of $22.00 per share (the “Offer Shares”).
  • Merus also granted the underwriters a 30-day option to purchase up to an additional 1,022,727 common shares (the “Option Shares” and together with the Offer Shares, the “Shares”).
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and excluding the underwriters’ option to purchase the Option Shares, are expected to be approximately $150.0 million.
  • All of the shares in the offering are to be sold by Merus.

Merus N.V. Announces Proposed Public Offering of Common Shares

Retrieved on: 
Wednesday, August 9, 2023

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten public offering of its common shares (the “Offer Shares”).

Key Points: 
  • UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten public offering of its common shares (the “Offer Shares”).
  • All of the common shares are being offered by Merus.
  • In addition, Merus expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Offer Shares (the “Option Shares” and together with the Offer Shares, the “Shares”).
  • The offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.